Akinaga, S.; Sugiyama, K.; Akiyama, T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: A new generation of anti-cancer agents for the new century? Anticancer Drug Des., 2000, 15(1), 43-52.
[PMID: 10888035]

Prudhomme, M. Rebeccamycin analogues as anti-cancer agents. Eur. J. Med. Chem., 2003, 38(2), 123-140.
[http://dx.doi.org/10.1016/S0223-5234(03)00011-4] [PMID: 12620658]

Mucke, H.A.M. CEP-1347 (Cephalon). IDrugs, 2003, 6(4), 377-383.
[PMID: 12789610]

a) Janosik, T.; Rannug, A.; Rannug, U.; Wahlström, N.; Slätt, J.; Bergman, J. Chemistry and properties of indolocarbazoles. Chem. Rev., 2018, 118(18), 9058-9128.
[http://dx.doi.org/10.1021/acs.chemrev.8b00186] [PMID: 30191712];
b) Knölker, H-J.; Reddy, K.R. Isolation and synthesis of biologically active carbazole alkaloids. Chem. Rev., 2002, 102(11), 4303-4427.
[http://dx.doi.org/10.1021/cr020059j] [PMID: 12428991]

Nakano, H. Ōmura, S. Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine J. Antibiot. (Tokyo), 2009, 62(1), 17-26.
[http://dx.doi.org/10.1038/ja.2008.4] [PMID: 19132059]

Rao, B.P.C.; Oliveira, O.N.; Varala, R. Strategies towards the synthesis of staurosporine indolocarbazole alkaloid and its analogues. scope of selective heterocycles from organic and pharmaceutical perspective; Intech Open, 2016, pp. 83-114.
[http://dx.doi.org/10.5772/63832]

Shewach, D.S.; Kuchta, R.D. Introduction to cancer chemotherapeutics. Chem. Rev., 2009, 109(7), 2859-2861.
[http://dx.doi.org/10.1021/cr900208x] [PMID: 19583428]

Cragg, G.M.; Newman, D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100(1-2), 72-79.
[http://dx.doi.org/10.1016/j.jep.2005.05.011] [PMID: 16009521]

Cragg, G.M.; Grothaus, P.G.; Newman, D.J. Impact of natural products on developing new anti-cancer agents. Chem. Rev., 2009, 109(7), 3012-3043.
[http://dx.doi.org/10.1021/cr900019j] [PMID: 19422222]

Sreedhar, A.S.; Csermely, P. Heat shock proteins in the regulation of apoptosis: New strategies in tumor therapy: A comprehensive review. Pharmacol. Ther., 2004, 101(3), 227-257.
[http://dx.doi.org/10.1016/j.pharmthera.2003.11.004] [PMID: 15031001]

Pechan, P.M. Heat shock proteins and cell proliferation. FEBS Lett., 1991, 280(1), 1-4.
[http://dx.doi.org/10.1016/0014-5793(91)80190-E] [PMID: 2009952]

McCubrey, J.A.; Steelman, L.S.; Abrams, S.L.; Lee, J.T.; Chang, F.; Bertrand, F.E.; Navolanic, P.M.; Terrian, D.M.; Franklin, R.A.; D’Assoro, A.B.; Salisbury, J.L.; Mazzarino, M.C.; Stivala, F.; Libra, M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul., 2006, 46(1), 249-279.
[http://dx.doi.org/10.1016/j.advenzreg.2006.01.004] [PMID: 16854453]

Lloyd, D.G.; Golfis, G.; Knox, A.J.; Fayne, D.; Meegan, M.J.; Oprea, T.I. Oncology exploration: Charting cancer medicinal chemistry space. Drug Discov. Today, 2006, 11(3-4), 149-159.
[http://dx.doi.org/10.1016/S1359-6446(05)03688-3] [PMID: 16533713]

Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov., 2005, 4(3), 206-220.
[http://dx.doi.org/10.1038/nrd1657] [PMID: 15729362]

Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66(7), 1022-1037.
[http://dx.doi.org/10.1021/np030096l] [PMID: 12880330]

Newman, D.J. Natural products as leads to potential drugs: An old process or the new hope for drug discovery? J. Med. Chem., 2008, 51(9), 2589-2599.
[http://dx.doi.org/10.1021/jm0704090] [PMID: 18393402]

a) Nettleton, D.E.; Doyle, T.W.; Krishnan, B.; Matsumoto, G.K.; Clardy, J. Isolation and structure of rebeccamycin - a new antitumor antibiotic from nocardia aerocoligenes. Tetrahedron Lett., 1985, 26(34), 4011-4014.
[http://dx.doi.org/10.1016/S0040-4039(00)89280-1];
b) Nettleton, D.E.; Bush, J.A.; Bradner, W.T.; Doyle, T.W. Process for producing rebeccamycin. US4552842 1985.;
c) Kaneko, T.; Wong, H.; Okamoto, K.T.; Clardy, J. Two synthetic approaches to rebeccamycin. Tetrahedron Lett., 1985, 26(34), 4015-4018.
[http://dx.doi.org/10.1016/S0040-4039(00)89281-3]

a) Prudhomme, M. Recent developments of rebeccamycin analogues as topoisomerase i inhibitors and antitumor agents. Curr. Med. Chem., 2000, 7(12), 1189-1212.
[http://dx.doi.org/10.2174/0929867003374138] [PMID: 11032967];
b) Xu, Y.; Her, C. Inhibition of topoisomerase (DNA) I (TOP1): DNA damage repair and anticancer therapy. Biomolecules, 2015, 5(3), 1652-1670.
[http://dx.doi.org/10.3390/biom5031652] [PMID: 26287259];
c) Pereira, E.R.; Belin, L.; Sancelme, M.; Prudhomme, M.; Ollier, M.; Rapp, M.; Sevère, D.; Riou, J.F.; Fabbro, D.; Meyer, T. Structure-activity relationships in a series of substituted indolocarbazoles: Topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J. Med. Chem., 1996, 39(22), 4471-4477.
[http://dx.doi.org/10.1021/jm9603779] [PMID: 8893841]

Sánchez, C.; Méndez, C.; Salas, J.A. Indolocarbazole natural products: Occurrence, biosynthesis, and biological activity. Nat. Prod. Rep., 2006, 23(6), 1007-1045.
[http://dx.doi.org/10.1039/B601930G] [PMID: 17119643]

Pommerehne, K.; Walisko, J.; Ebersbach, A.; Krull, R. The antitumor antibiotic rebeccamycin-challenges and advanced approaches in production processes. Appl. Microbiol. Biotechnol., 2019, 103(9), 3627-3636.
[http://dx.doi.org/10.1007/s00253-019-09741-y] [PMID: 30888461]

Nouioui, I.; Carro, L.; García-López, M.; Meier-Kolthoff, J.P.; Woyke, T.; Kyrpides, N.C.; Pukall, R.; Klenk, H-P.; Goodfellow, M.; Göker, M. Genome-based taxonomic classification of the phylum Actinobacteria. Front. Microbiol., 2018, 9, 2007.
[http://dx.doi.org/10.3389/fmicb.2018.02007] [PMID: 30186281]

Long, B.H.; Rose, W.C.; Vyas, D.M.; Matson, J.A.; Forenza, S. Discovery of antitumor indolocarbazoles: Rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Curr. Med. Chem. Anticancer Agents, 2002, 2(2), 255-266.
[http://dx.doi.org/10.2174/1568011023354218] [PMID: 12678746]

Matson, J.A. Process for preparing 4'-deschlororebeccamycin U.S. 45671431986.

Lam, K.S.; McDonald, L.; Mattei, J.; Forenza, S.; Matson, J.A.U.S. U.S. 5326754. 1994.

Bush, J.A.; Long, B.H.; Catino, J.J.; Bradner, W.T.; Tomita, K. Production and biological activity of rebeccamycin, a novel antitumor agent. J. Antibiot. (Tokyo), 1987, 40(5), 668-678.
[http://dx.doi.org/10.7164/antibiotics.40.668] [PMID: 3112080]

Kaneko, T.; Wong, H.; Utzig, J.; Schurig, J.; Doyle, T. Water soluble derivatives of rebeccamycin. J. Antibiot. (Tokyo), 1990, 43(1), 125-127.
[http://dx.doi.org/10.7164/antibiotics.43.125] [PMID: 2307626]

Bailly, C.; Colson, P.; Houssier, C.; Rodrigues-Pereira, E.; Prudhomme, M.; Waring, M.J. Recognition of specific sequences in DNA by a topoisomerase i inhibitor derived from the antitumor drug rebeccamycin. Mol. Pharmacol., 1998, 53(1), 77-87.
[http://dx.doi.org/10.1124/mol.53.1.77] [PMID: 9443934]

Pommier, Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer, 2006, 6(10), 789-802.
[http://dx.doi.org/10.1038/nrc1977] [PMID: 16990856]

Rewcastle, G.W. Becatecarin (Helsinn Healthcare). IDrugs, 2005, 8(10), 838-847.
[PMID: 16254805]

Fabre, S.; Prudhomme, V.; Rapp, M. Preparation of synthons for the synthesis of protein kinase C inhibitors from rebeccamycin. Bioorg. Med. Chem. Lett., 1992, 2(5), 449-452.
[http://dx.doi.org/10.1016/S0960-894X(00)80167-5]

Fabre, S.; Prudhomme, M.; Sancelme, M.; Rapp, M. Indolocarbazole protein kinase C inhibitors from rebeccamycin. Bioorg. Med. Chem., 1994, 2(2), 73-77.
[http://dx.doi.org/10.1016/S0968-0896(00)82003-9] [PMID: 7922125]

a) Bailly, C.; Riou, J-F.; Colson, P.; Houssier, C.; Rodrigues-Pereira, E.; Prudhomme, M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry, 1997, 36(13), 3917-3929.
[http://dx.doi.org/10.1021/bi9624898] [PMID: 9092822];
b) Bailly, C.; Qu, X.; Graves, D.E.; Prudhomme, M.; Chaires, J.B. Calories from carbohydrates: Energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition. Chem. Biol., 1999, 6(5), 277-286.
[http://dx.doi.org/10.1016/S1074-5521(99)80073-8] [PMID: 10322124];
c) Bailly, C.; Goossens, J-F.; Laine, W.; Anizon, F.; Prudhomme, M.; Ren, J.; Chaires, J.B. Formaldehyde-induced alkylation of a 2′-aminoglucose rebeccamycin derivative to both A.T and G.C base pairs in DNA. J. Med. Chem., 2000, 43(24), 4711-4720.
[http://dx.doi.org/10.1021/jm0003438] [PMID: 11101362];
d) Bailly, C.; Qu, X.; Anizon, F.; Prudhomme, M.; Riou, J-F.; Chaires, J.B. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol. Pharmacol., 1999, 55(2), 377-385.
[http://dx.doi.org/10.1124/mol.55.2.377] [PMID: 9927631]

Anizon, F.; Belin, L.; Moreau, P.; Sancelme, M.; Voldoire, A.; Prudhomme, M.; Ollier, M.; Sevère, D.; Riou, J-F.; Bailly, C.; Fabbro, D.; Meyer, T. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem., 1997, 40(21), 3456-3465.
[http://dx.doi.org/10.1021/jm9702084] [PMID: 9341921]

Moreau, P.; Anizon, F.; Sancelme, M.; Prudhomme, M.; Bailly, C.; Sevère, D.; Riou, J-F.; Fabbro, D.; Meyer, T.; Aubertin, A-M. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. J. Med. Chem., 1999, 42(4), 584-592.
[http://dx.doi.org/10.1021/jm980396d] [PMID: 10052965]

Moreau, P.; Anizon, F.; Sancelme, M.; Prudhomme, M.; Sevère, D.; Riou, J-F.; Goossens, J-F.; Hénichart, J-P.; Bailly, C.; Labourier, E.; Tazzi, J.; Fabbro, D.; Meyer, T.; Aubertin, A.M. Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives. J. Med. Chem., 1999, 42(10), 1816-1822.
[http://dx.doi.org/10.1021/jm980702n] [PMID: 10346933]

Lakatosh, S.A.; Balzarini, J.; Andrei, G.; Snoeck, R.; Lakatosh, A.; De Clercq, E.; Preobrazhenskaya, M.N. Synthesis, and cytotoxic activity of N(ind)-alkoxy derivatives of antibiotic arcyriarubin and dechloro-rebeccamycin aglycon. J. Antibiot. (Tokyo), 2002, 55(8), 768-773.
[http://dx.doi.org/10.7164/antibiotics.55.768] [PMID: 12374389]

Marminon, C.; Anizon, F.; Moreau, P.; Léonce, S.; Pierré, A.; Pfeiffer, B.; Renard, P.; Prudhomme, M. Syntheses and antiproliferative activities of new rebeccamycin derivatives with the sugar unit linked to both indole nitrogens. J. Med. Chem., 2002, 45(6), 1330-1339.
[http://dx.doi.org/10.1021/jm011045t] [PMID: 11882002]

Marminon, C.; Pierré, A.; Pfeiffer, B.; Pérez, V.; Léonce, S.; Renard, P.; Prudhomme, M. Syntheses and antiproliferative activities of rebeccamycin analogues bearing two 7-azaindole moieties. Bioorg. Med. Chem., 2003, 11(5), 679-687.
[http://dx.doi.org/10.1016/S0968-0896(02)00532-1] [PMID: 12537997]

Moreau, P.; Gaillard, N.; Marminon, C.; Anizon, F.; Dias, N.; Baldeyrou, B.; Bailly, C.; Pierré, A.; Hickman, J.; Pfeiffer, B.; Renard, P.; Prudhomme, M. Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives. Bioorg. Med. Chem., 2003, 11(23), 4871-4879.
[http://dx.doi.org/10.1016/j.bmc.2003.09.014] [PMID: 14604648]

Faul, M.M.; Sullivan, K.A.; Grutsch, J.L.; Winneroski, L.L.; Shih, C.; Sanchez-Martinez, C.; Cooper, J.T. Synthesis of indolo[2,3-a]carbazole glycoside analogs of rebeccamycin: Inhibitors of cyclin D1-CDK4. Tetrahedron Lett., 2004, 45(5), 1095-1098.
[http://dx.doi.org/10.1016/j.tetlet.2003.10.184]

Zhang, G.; Shen, J.; Cheng, H.; Zhu, L.; Fang, L.; Luo, S.; Muller, M.T.; Lee, G.E.; Wei, L.; Du, Y.; Sun, D.; Wang, P.G. Syntheses and biological activities of rebeccamycin analogues with uncommon sugars. J. Med. Chem., 2005, 48(7), 2600-2611.
[http://dx.doi.org/10.1021/jm0493764] [PMID: 15801850]

Messaoudi, S.; Anizon, F.; Léonce, S.; Pierré, A.; Pfeiffer, B.; Prudhomme, M. Synthesis and cytotoxicities of 7-aza rebeccamycin analogues bearing various substituents on the sugar moiety, on the imide nitrogen and on the carbazole framework. Eur. J. Med. Chem., 2005, 40(10), 961-971.
[http://dx.doi.org/10.1016/j.ejmech.2005.04.002] [PMID: 15907347]

Messaoudi, S.; Anizon, F.; Peixoto, P.; David-Cordonnier, M-H.; Golsteyn, R.M.; Léonce, S.; Pfeiffer, B.; Prudhomme, M. Synthesis and biological activities of 7-aza rebeccamycin analogues bearing the sugar moiety on the nitrogen of the pyridine ring. Bioorg. Med. Chem., 2006, 14(22), 7551-7562.
[http://dx.doi.org/10.1016/j.bmc.2006.07.013] [PMID: 16889964]

Animati, F.; Berettoni, M.; Bigioni, M.; Binaschi, M.; Felicetti, P.; Gontrani, L.; Incani, O.; Madami, A.; Monteagudo, E.; Olivieri, L.; Resta, S.; Rossi, C.; Cipollone, A. Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety. ChemMedChem, 2008, 3(2), 266-279.
[http://dx.doi.org/10.1002/cmdc.200700232] [PMID: 18157856]

Anizon, F.; Golsteyn, R.M.; Léonce, S.; Pfeiffer, B.; Prudhomme, M. A three-step synthesis from rebeccamycin of an efficient checkpoint kinase 1 inhibitor. Eur. J. Med. Chem., 2009, 44(5), 2234-2238.
[http://dx.doi.org/10.1016/j.ejmech.2008.05.023] [PMID: 18602198]

Animati, F.; Berettoni, M.; Bigioni, M.; Binaschi, M.; Cipollone, A.; Irrissuto, C.; Nardelli, F.; Olivieri, L. Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety. Bioorg. Med. Chem. Lett., 2012, 22(15), 5013-5017.
[http://dx.doi.org/10.1016/j.bmcl.2012.06.016] [PMID: 22749423]

Marminon, C.; Anizon, F.; Moreau, P.; Pfeiffer, B.; Pierré, A.; Golsteyn, R.M.; Peixoto, P.; Hildebrand, M.P.; David-Cordonnier, M.H.; Lozach, O.; Meijer, L.; Prudhomme, M. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors. Mol. Pharmacol., 2008, 74(6), 1620-1629.
[http://dx.doi.org/10.1124/mol.108.049346] [PMID: 18768386]

Van Arnam, E.B.; Ruzzini, A.C.; Sit, C.S.; Currie, C.R.; Clardy, J. Rebeccamycin analog provides plasmid-encoded niche defense. J. Am. Chem. Soc., 2015, 137(45), 14272-14274.
[http://dx.doi.org/10.1021/jacs.5b09794] [PMID: 26535611]

Matson, J.A.; Claridge, C.; Bush, J.A.; Titus, J.; Bradner, W.T.; Doyle, T.W.; Horan, A.C.; Patel, M. AT2433-A1, AT2433-A2, AT2433-B1, and AT2433-B2 novel antitumorantibiotic compounds produced by actinomaduramelliaura. J. Antibiot. (Tokyo), 1989, 42(11), 1547-1555.
[http://dx.doi.org/10.7164/antibiotics.42.1547] [PMID: 2584136]

Dowlati, A.; Posey, J.; Ramanathan, R.K.; Rath, L.; Fu, P.; Chak, A.; Krishnamurthi, S.; Brell, J.; Ingalls, S.; Hoppel, C.L.; Ivy, P.; Remick, S.C. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemother. Pharmacol., 2009, 65(1), 73-78.
[http://dx.doi.org/10.1007/s00280-009-1005-x] [PMID: 19399502]

Borthakur, G.; Alvarado, Y.; Ravandi-Kashani, F.; Cortes, J.; Estrov, Z.; Faderl, S.; Ivy, P.; Bueso-Ramos, C.; Nebiyou Bekele, B.; Giles, F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer, 2008, 113(2), 360-366.
[http://dx.doi.org/10.1002/cncr.23559] [PMID: 18473351]

Langevin, A.M.; Bernstein, M.; Kuhn, J.G.; Blaney, S.M.; Ivy, P.; Sun, J.; Chen, Z.; Adamson, P.C. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: A children’s oncology group study. Pediatr. Blood Cancer, 2008, 50(3), 577-580.
[http://dx.doi.org/10.1002/pbc.21274] [PMID: 17610262]

Lam, K.S.; Schroeder, D.R.; Veitch, J.M.; Matson, J.A.; Forenza, S. Isolation of a bromo analog of rebeccamycin from Saccharothrix aerocolonigenes. J. Antibiot. (Tokyo), 1991, 44(9), 934-939.
[http://dx.doi.org/10.7164/antibiotics.44.934] [PMID: 1938615]

Pearce, C.J.; Doyle, T.W.; Forenza, S.; Lam, K.S.; Schroeder, D.R. The biosynthetic origins of rebeccamycin. J. Nat. Prod., 1988, 51(5), 937-940.
[http://dx.doi.org/10.1021/np50059a020] [PMID: 3204382]

Schwandt, A.; Mekhail, T.; Halmos, B.; O’Brien, T.; Ma, P.C.; Fu, P.; Ivy, P.; Dowlati, A. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed “sensitive” small cell lung cancer. J. Thorac. Oncol., 2012, 7(4), 751-754.
[http://dx.doi.org/10.1097/JTO.0b013e31824abca2] [PMID: 22425925]

Burstein, H.J.; Overmoyer, B.; Gelman, R.; Silverman, P.; Savoie, J.; Clarke, K.; Dumadag, L.; Younger, J.; Ivy, P.; Winer, E.P. Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules. Invest. New Drugs, 2007, 25(2), 161-164.
[http://dx.doi.org/10.1007/s10637-006-9007-6] [PMID: 16969707]

Dowlati, A.; Chapman, R.; Subbiah, S.; Fu, P.; Ness, A.; Cortas, T.; Patrick, L.; Reynolds, S.; Xu, N.; Levitan, N.; Ivy, P.; Remick, S.C. Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. Invest. New Drugs, 2005, 23(6), 563-567.
[http://dx.doi.org/10.1007/s10637-005-0754-6] [PMID: 16034518]

Nock, C.J.; Brell, J.M.; Bokar, J.A.; Cooney, M.M.; Cooper, B.; Gibbons, J.; Krishnamurthi, S.; Manda, S.; Savvides, P.; Remick, S.C.; Ivy, P.; Dowlati, A. A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Invest. New Drugs, 2011, 29(1), 126-130.
[http://dx.doi.org/10.1007/s10637-009-9322-9] [PMID: 19774342]

Goel, S.; Wadler, S.; Hoffman, A.; Volterra, F.; Baker, C.; Nazario, E.; Ivy, P.; Silverman, A.; Mani, S. A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer. Invest. New Drugs, 2003, 21(1), 103-107.
[http://dx.doi.org/10.1023/A:1022980613420] [PMID: 12795535]

Hussain, M.; Vaishampayan, U.; Heilbrun, L.K.; Jain, V.; LoRusso, P.M.; Ivy, P.; Flaherty, L. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer. Invest. New Drugs, 2003, 21(4), 465-471.
[http://dx.doi.org/10.1023/A:1026259503954] [PMID: 14586215]

Lam, K.S.; Forenza, S.; Doyle, T.W.; Pearce, C.J. Identification of indolepyruvic acid as an intermediate of rebeccamycin biosynthesis. J. Ind. Microbiol., 1990, 6(4), 291-294.
[http://dx.doi.org/10.1007/BF01575876] [PMID: 1366997]

Sánchez, C.; Butovich, I.A.; Braña, A.F.; Rohr, J.; Méndez, C.; Salas, J.A. The biosynthetic gene cluster for the antitumor rebeccamycin: Characterization and generation of indolocarbazole derivatives. Chem. Biol., 2002, 9(4), 519-531.
[http://dx.doi.org/10.1016/S1074-5521(02)00126-6] [PMID: 11983340]

Sánchez, C.; Zhu, L.; Braña, A.F.; Salas, A.P.; Rohr, J.; Méndez, C.; Salas, J.A. Combinatorial biosynthesis of antitumor indolocarbazole compounds. Proc. Natl. Acad. Sci. USA, 2005, 102(2), 461-466.
[http://dx.doi.org/10.1073/pnas.0407809102] [PMID: 15625109]

Onaka, H.; Taniguchi, S.; Igarashi, Y.; Furumai, T. Characterization of the biosynthetic gene cluster of rebeccamycin from Lechevalieria aerocolonigenes ATCC 39243. Biosci. Biotechnol. Biochem., 2003, 67(1), 127-138.
[http://dx.doi.org/10.1271/bbb.67.127] [PMID: 12619684]

Hyun, C.G.; Bililign, T.; Liao, J.; Thorson, J.S. The biosynthesis of indolocarbazoles in a heterologous E. coli host. ChemBioChem, 2003, 4(1), 114-117.
[http://dx.doi.org/10.1002/cbic.200390004] [PMID: 12512086]

Nishizawa, T.; Aldrich, C.C.; Sherman, D.H. Molecular analysis of the rebeccamycin L-amino acid oxidase from Lechevalieria aerocolonigenes ATCC 39243. J. Bacteriol., 2005, 187(6), 2084-2092.
[http://dx.doi.org/10.1128/JB.187.6.2084-2092.2005] [PMID: 15743957]

Howard-Jones, A.R.; Walsh, C.T. Enzymatic generation of the chromopyrrolic acid scaffold of rebeccamycin by the tandem action of RebO and RebD. Biochemistry, 2005, 44(48), 15652-15663.
[http://dx.doi.org/10.1021/bi051706e] [PMID: 16313168]

Yeh, E.; Garneau, S.; Walsh, C.T. Robust in vitro activity of RebF and RebH, a two-component reductase/halogenase, generating 7-chlorotryptophan during rebeccamycin biosynthesis. Proc. Natl. Acad. Sci. USA, 2005, 102(11), 3960-3965.
[http://dx.doi.org/10.1073/pnas.0500755102] [PMID: 15743914]

Yeh, E.; Cole, L.J.; Barr, E.W.; Bollinger, J.M., Jr; Ballou, D.P.; Walsh, C.T. Flavin redox chemistry precedes substrate chlorination during the reaction of the flavin-dependent halogenase RebH. Biochemistry, 2006, 45(25), 7904-7912.
[http://dx.doi.org/10.1021/bi060607d] [PMID: 16784243]

Sánchez, C.; Méndez, C.; Salas, J.A. Engineering biosynthetic pathways to generate antitumor indolocarbazole derivatives. J. Ind. Microbiol. Biotechnol., 2006, 33(7), 560-568.
[http://dx.doi.org/10.1007/s10295-006-0092-5] [PMID: 16491358]

Zhang, C.; Albermann, C.; Fu, X.; Peters, N.R.; Chisholm, J.D.; Zhang, G.; Gilbert, E.J.; Wang, P.G.; Van Vranken, D.L.; Thorson, J.S. RebG- and RebM-catalyzed indolocarbazole diversification. ChemBioChem, 2006, 7(5), 795-804.
[http://dx.doi.org/10.1002/cbic.200500504] [PMID: 16575939]

Nishizawa, T.; Grüschow, S.; Jayamaha, D.H.E.; Nishizawa-Harada, C.; Sherman, D.H. Enzymatic assembly of the bis-indole core of rebeccamycin. J. Am. Chem. Soc., 2006, 128(3), 724-725.
[http://dx.doi.org/10.1021/ja056749x] [PMID: 16417354]

Zhang, C.; Weller, R.L.; Thorson, J.S.; Rajski, S.R. Natural product diversification using a non-natural cofactor analogue of S-adenosyl-L-methionine. J. Am. Chem. Soc., 2006, 128(9), 2760-2761.
[http://dx.doi.org/10.1021/ja056231t] [PMID: 16506729]

Howard-Jones, A.R.; Walsh, C.T. Staurosporine and rebeccamycin aglycones are assembled by the oxidative action of StaP, StaC, and RebC on chromopyrrolic acid. J. Am. Chem. Soc., 2006, 128(37), 12289-12298.
[http://dx.doi.org/10.1021/ja063898m] [PMID: 16967980]

Yeh, E.; Blasiak, L.C.; Koglin, A.; Drennan, C.L.; Walsh, C.T. Chlorination by a long-lived intermediate in the mechanism of flavin-dependent halogenases. Biochemistry, 2007, 46(5), 1284-1292.
[http://dx.doi.org/10.1021/bi0621213] [PMID: 17260957]

Howard-Jones, A.R.; Walsh, C.T. Nonenzymatic oxidative steps accompanying action of the cytochrome P450 enzymes StaP and RebP in the biosynthesis of staurosporine and rebeccamycin. J. Am. Chem. Soc., 2007, 129(36), 11016-11017.
[http://dx.doi.org/10.1021/ja0743801] [PMID: 17705392]

Ryan, K.S.; Howard-Jones, A.R.; Hamill, M.J.; Elliott, S.J.; Walsh, C.T.; Drennan, C.L. Crystallographic trapping in the rebeccamycin biosynthetic enzyme RebC. Proc. Natl. Acad. Sci. USA, 2007, 104(39), 15311-15316.
[http://dx.doi.org/10.1073/pnas.0707190104] [PMID: 17873060]

Ryan, K.S.; Howard-Jones, A.R.; Walsh, C.T.; Drennan, C.L. Crystal structure of RebC, a flavoprotein involved in rebaccamycin biosynthesis. FASEB J., 2007, 21(6), A1043-A1043.

Singh, S.; McCoy, J.G.; Zhang, C.; Bingman, C.A.; Phillips, G.N., Jr; Thorson, J.S. Structure and mechanism of the rebeccamycin sugar 4′-O-methyltransferase RebM. J. Biol. Chem., 2008, 283(33), 22628-22636.
[http://dx.doi.org/10.1074/jbc.M800503200] [PMID: 18502766]

Groom, K.; Bhattacharya, A.; Zechel, D.L. Rebeccamycin and staurosporine biosynthesis: Insight into the mechanisms of the flavin-dependent monooxygenases RebC and StaC. ChemBioChem, 2011, 12(3), 396-400.
[http://dx.doi.org/10.1002/cbic.201000580] [PMID: 21290541]

Asamizu, S.; Shiro, Y.; Igarashi, Y.; Nagano, S.; Onaka, H. Characterization and functional modification of StaC and RebC, which are involved in the pyrrole oxidation of indolocarbazole biosynthesis. Biosci. Biotechnol. Biochem., 2011, 75(11), 2184-2193.
[http://dx.doi.org/10.1271/bbb.110474] [PMID: 22056432]

Spolitak, T.; Ballou, D.P. Evidence for catalytic intermediates involved in generating the chromopyrrolic acid scaffold of rebeccamycin by RebO and RebD. Arch. Biochem. Biophys., 2015, 573, 111-119.
[http://dx.doi.org/10.1016/j.abb.2015.03.020] [PMID: 25837855]

Zenkov, R.G.; Ektova, L.V.; Vlasova, O.A.; Belitskiy, G.A.; Yakubovskaya, M.G.; Kirsanov, K.I. Indolo[2,3-a]carbazoles: Diversity, biological properties, application in antitumor therapy. Chem. Heterocycl. Compd., 2020, 56(6), 644-658.
[http://dx.doi.org/10.1007/s10593-020-02714-4]

Chambers, G.E.; Sayan, A.E.; Brown, R.C.D. The synthesis of biologically active indolocarbazole natural products. Nat. Prod. Rep., 2021, 38(10), 1794-1820.
[http://dx.doi.org/10.1039/D0NP00096E] [PMID: 33666619]

Gallant, M.; Link, J.T.; Danishefsky, S.J. A stereoselective synthesis of indole-.beta.-N-glycosides: An application to the synthesis of rebeccamycin. J. Org. Chem., 1993, 58(2), 343-349.
[http://dx.doi.org/10.1021/jo00054a015]

Faul, M.M.; Winneroski, L.L.; Krumrich, C.A. Synthesis of rebeccamycin and 11-Dechlororebeccamycin. J. Org. Chem., 1999, 64(7), 2465-2470.
[http://dx.doi.org/10.1021/jo982277b]